Enliven Therapeutics, Inc. ELVN 深 沪
等待开盘 10-14 09:30:00 美东时间
39.49
-1.350
-3.31%
华盛通- 最 高40.99
- 今 开40.56
- 成交量 84.79万股
- 最 低 39.27
- 昨 收 40.84
- 总市值 28.93亿
- 52周最高 62.32
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 14.785
- 委 比 -80.65%
- 总股本 7327.08万
- 历史最高 250.84
- 量 比 0.60
- 振 幅 4.21%
- 历史最低 3.896
- 每 手 1
- 风险率 13.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75
JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.
10-01 22:46
Enliven Therapeutics to Present at Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and ...
09-04 04:05
Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and ...
09-01 15:57
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML). ELVN-001 Shows Positive Phase 1 Data Enliven Therapeutics’ lea...
08-19 01:58
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
08-18 19:48
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.
08-06 19:26
Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last year.
08-06 04:49
